Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin
Jin Zhong, Pengbo Sun, Naihan Xu, et al.
Biochemical Pharmacology (2020) Vol. 175, pp. 113856-113856
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression
Milad Ashrafizadeh, Sepideh Mirzaei, Mohammad Gholami, et al.
Carbohydrate Polymers (2021) Vol. 272, pp. 118491-118491
Open Access | Times Cited: 133
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Sepideh Mirzaei, Mohammad Gholami, Farid Hashemi, et al.
Drug Discovery Today (2021) Vol. 27, Iss. 2, pp. 436-455
Open Access | Times Cited: 127
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Roberto Mattioli, Andrea Ilari, Beatrice Colotti, et al.
Molecular Aspects of Medicine (2023) Vol. 93, pp. 101205-101205
Open Access | Times Cited: 103
SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 67
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review
Jinyun Dong, Yuan Li, Can Hu, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108488-108488
Closed Access | Times Cited: 58
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 15
Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity
Milad Ashrafizadeh, Ali Zarrabi, Farid Hashemi, et al.
Pharmaceutics (2020) Vol. 12, Iss. 11, pp. 1084-1084
Open Access | Times Cited: 102
P-Glycoprotein Aggravates Blood Brain Barrier Dysfunction in Experimental Ischemic Stroke by Inhibiting Endothelial Autophagy
Liangliang Huang, Yan Chen, Rui Liu, et al.
Aging and Disease (2022) Vol. 13, Iss. 5, pp. 1546-1546
Open Access | Times Cited: 42
Doxorubicin conjugates: a practical approach for its cardiotoxicity alleviation
Abed Alqader Ibrahim, Hamdi Nsairat, Mazen Al-Sulaibi, et al.
Expert Opinion on Drug Delivery (2024) Vol. 21, Iss. 3, pp. 399-422
Closed Access | Times Cited: 7
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Research Progress of SGLT2 Inhibitors in Cancer Treatment
Xiaoyong Miao, Jianing Zhang, Weiyan Huang, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 505-514
Open Access
(+)-Borneol enhances the protective effect edaravone against cerebral ischemia/reperfusion injury by targeting OAT3/P-gp transporters for drug delivery into the brain
Xinming Wang, Junjin Liu, X.Z. Zheng, et al.
Phytomedicine (2025) Vol. 139, pp. 156521-156521
Closed Access
Streptozotocin-induced hyperglycemia unmasks cardiotoxicity induced by doxorubicin
Martin Nicol, Benjamin Deniau, Roza Rahli, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Kristy T. K. Lau, Lui Ng, Jason W.H. Wong, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 1121-1136
Closed Access | Times Cited: 35
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
Olga‐Demetra Biziotis, Evangelia E. Tsakiridis, Amr Ali, et al.
Molecular Oncology (2023) Vol. 17, Iss. 11, pp. 2235-2256
Open Access | Times Cited: 12
Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway
Jingyi Luo, Pengbo Sun, Xun Zhang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13336-13336
Open Access | Times Cited: 30
Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway
Pengbo Sun, Yangyang Wang, Yipei Ding, et al.
iScience (2021) Vol. 24, Iss. 6, pp. 102521-102521
Open Access | Times Cited: 28
Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin
Haoning Huang, Fan‐Lu Kung, Yu‐Wen Huang, et al.
Biochemical Pharmacology (2024) Vol. 223, pp. 116140-116140
Closed Access | Times Cited: 3
Recent advances and future directions in anti‐tumor activity of cryptotanshinone: A mechanistic review
Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, et al.
Phytotherapy Research (2020) Vol. 35, Iss. 1, pp. 155-179
Closed Access | Times Cited: 28
Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
Jingyi Luo, Pengbo Sun, Yangyang Wang, et al.
European Journal of Pharmacology (2021) Vol. 907, pp. 174304-174304
Closed Access | Times Cited: 26
When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy
Linna Yu, Yi Jin, Mingjie Song, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1589-1589
Open Access | Times Cited: 17
Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy
Ali Zarrabi, Anupam Bishayee, Sepideh Mirzaei, et al.
Current Molecular Pharmacology (2022) Vol. 16, Iss. 3, pp. 280-306
Closed Access | Times Cited: 14
Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases
Kazuhiko Fukushima, Shinji Kitamura, Kenji Tsuji, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 19
Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway
Wenhui Hao, Wenjie Shan, Fang Wan, et al.
Antioxidants (2023) Vol. 12, Iss. 4, pp. 838-838
Open Access | Times Cited: 7
The effects and mechanisms of aloe‐emodin on reversing adriamycin‐induced resistance of MCF‐7/ADR cells
Guorong Cheng, Zifeng Pi, Xiaoyu Zhuang, et al.
Phytotherapy Research (2021) Vol. 35, Iss. 7, pp. 3886-3897
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top